The short version of GHRH analogue fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-23 and is reviewed periodically as new material appears.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
All surface ships, as well as surfaced submarines, are in a positively buoyant condition, weighing less than the volume of water they would displace if fully submerged. To submerge hydrostatically, a ship must have negative buoyancy, either by increasing its own weight or decreasing its displacement of water. To control their displacement and weight, submarines have ballast tanks, which can hold varying amounts of water and air. For general submersion or surfacing, submarines use the main ballast tanks (MBTs), which are ambient pressure tanks, filled with water to submerge or with air to surface. While submerged, MBTs generally remain flooded, which simplifies their design, and on many submarines, these tanks are a section of the space between the light hull and the pressure hull. For more precise control of depth, submarines use smaller depth control tanks (DCTs)—also called hard tanks (due to their ability to withstand higher pressure) or trim tanks. These are variable buoyancy pressure vessels, a type of buoyancy control device. The amount of water in depth control tanks can be adjusted to hydrostatically change depth or to maintain a constant depth as outside conditions (mainly water density) change. Depth control tanks may be located either near the submarine's center of gravity, to minimise the effect on trim, or separated along the length of the hull so they can also be used to adjust static trim by transfer of water between them.
This can be applied to find the best substrates for proteolytic enzymes. The substrate is displayed on the bacterial cell surface between an affinity ligand and the scaffold, and the kinetics of substrate proteolysis is measured using FACS. Bacterial display can be used to find peptides which bind to specific cells e.g. breast cancer cells or stem cells. Displayed proteins are fluorescently tagged with GFP, so binding interactions between peptides and target cells can be seen by flow cytometry. Control samples are required in order to measure fluorescence levels in the absence of displayed peptides. Samples are also required which don’t contain displayed peptides, but contain mammalian cells and bacterial cells (including the scaffold). Vaccine delivery is a very common application of bacterial surface display. There are two types of live bacterial vaccines that can be made:
=== Neo === Counter-Strike Neo (stylized NEO) is a Japanese arcade adaptation of Counter-Strike published by Namco for Linux-based machines. The game is set in a futuristic version of Counter-Strike, with characters featuring anime-like designs. A selection of single-player missions, mini-games, and seasonal events were added to prolong the players' interest on the game.
=== Industry corruption of psychiatric prescribing and research === Prescription of psychiatric drugs is partly due to lobbying by drug companies that distorts research. Cosgrove, Logan, and Herrawi (2022) argue that "the prevalence of academic-industry relationships and financial conflicts of interest in psychiatry" has biased academic research towards reporting favorable risk-benefit ratios of psychiatric drugs.
Sources: en.wikipedia.org
These excitations result in excited state absorption peaks located below the diagonal and cross peaks. In 2DNMR, two distinct techniques, COSY and NOESY, are frequently used. The cross peaks in the first are related to the scalar coupling, while in the latter they are related to the spin transfer between different nuclei. In nonlinear two-dimensional infrared spectroscopy, analogs have been drawn to these 2DNMR techniques. Nonlinear two-dimensional infrared spectroscopy with zero waiting time corresponds to COSY, and nonlinear two-dimensional infrared spectroscopy with finite waiting time allowing vibrational population transfer corresponds to NOESY. The COSY variant of nonlinear two-dimensional infrared spectroscopy has been used for determination of the secondary structure content of proteins.
== History == 4-HO-NiPT was first described in the scientific literature, as a metabolite of 4-AcO-DiPT, in 2022. Subsequently, its synthesis was described in 2023 and its pharmacology was reported in 2024. The drug was reported as a possible novel designer drug online in 2022.
Representative desserts are buñuelos, natillas, Maria Luisa cake, bocadillo made of guayaba (guava jelly), cocadas (coconut balls), casquitos de guayaba (candied guava peels), torta de natas, obleas, flan de mango, roscón, milhoja, manjar blanco, dulce de feijoa, dulce de papayuela, torta de mojicón, and esponjado de curuba. Typical sauces (salsas) are hogao (tomato and onion sauce) and Colombian-style ají. Some representative beverages are coffee (Tinto), champús, cholado, lulada, avena colombiana, sugarcane juice, aguapanela, aguardiente, hot chocolate and fresh fruit juices (often made with water or milk).
For instance, Captopril® (Enalapril), Integrilin® (Eptifibatide) and Aggrastat® (Tirofiban) are drugs based on snake venoms, which have been approved by the FDA. In addition to these approved drugs, many other snake venom components are now involved in preclinical or clinical trials for a variety of therapeutic applications.
Powys covers the historic counties of Montgomeryshire and Radnorshire, most of Brecknockshire, and part of historic Denbighshire. With an area of about 2,000 square miles (5,200 km2), it is now the largest administrative area in Wales by land and area (Dyfed was until 1996 before several former counties created by the Local Government Act 1972 were abolished). It is bounded to the north by Gwynedd, Denbighshire and Wrexham County Borough; to the west by Ceredigion and Carmarthenshire; to the east by Shropshire and Herefordshire; and to the south by Rhondda Cynon Taf, Merthyr Tydfil County Borough, Caerphilly County Borough, Blaenau Gwent, Monmouthshire and Neath Port Talbot. The largest towns are Newtown, Ystradgynlais, Brecon, Welshpool, Llandrindod Wells and Knighton. Powys has the lowest population density of all the principal areas of Wales. Most of Powys is mountainous, and most roads and railways are relatively slow. Just under a third of the residents have Welsh linguistic skills: Welsh speakers are concentrated mainly in the rural areas both in and around Machynlleth, Llanfyllin and Llanrhaeadr-ym-Mochnant (where William Morgan first translated the whole Bible into Welsh in 1588) in Montgomeryshire, and the industrial area of Ystradgynlais in the southwest of Brecknockshire. In Radnorshire, the language survived into the 20th century west of Rhayader with a few native speakers from Nantmel parish surviving into the 20th century too.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.